Business Wire

ELICIT PLANT, the Future World Champion That Helps the Field Crop Industry Tackle Water Stress and Scarcity

Share

One year after joining the French Tech Agri 20 program, Agri-tech company ELICIT PLANT has joined the circle of the 100 most strategic and innovative French companies for France by 2030, as part of the French Tech 2030 program.

Following a rigorous selection process led by the French General Secretariat for Investment – the body in charge of the France 2030 program – with the help of all French government departments and Bpifrance, ELICIT PLANT, a pioneering company at the forefront of the fight against the impact of climate change on agriculture, and in particular on field crops (corn, wheat, soy and sunflower), has made a striking entrance into the first edition of the French Tech 2030 program.

The initiative aims to provide great public support to one hundred or so innovative companies, in a context of highly aggressive international competition, so as to position them as world leaders by 2030, by providing:

  • Financial support, provided by France 2030 operators,
  • Extra-financial support measures: export, business opportunities, global economic influence strategy, increased visibility.

This announcement adds to the legitimacy of the track record and international development of ELICIT PLANT, the developer of the first phytosterol-based ecological innovation for the agricultural industry, the only widely available technology scale that allows for significant field crop yield gains in an increasingly critical climatic context.

Several French departements are being affected by drought even before the start of the summer season, leaving public authorities no other option but to impose water restrictions in certain areas. The risk of drought is now accepted as fact in a number of regions. This is cause for concern among scientists, who fear that the summer of 2023 will be even more difficult than 2022.

ELICIT PLANT, the biotech that pioneers phytosterols to help the field crop industry combat water stress

The flagship BEST-a product designed for corn production reduces water consumption by up to 20%, and is in high demand in France, Brazil and Ukraine, with over 100 cooperative customers.

In 2023, the ELICIT PLANT innovation will be distributed to 100 coops and distributors, addressing a total potential of 100,000 corn growers and 10 million hectares of corn in France, Brazil and Ukraine.

ELICIT PLANT has created at the heart of its open-field laboratory based in Moulins-sur-Tardoire a technological platform called EliTerra® that will enable the company to develop new products designed for the culture of wheat and barley in Europe, of sunflower in Ukraine and of soybeans for the Brazilian market. Marketing authorization applications are also underway in the United States.

“We are very proud to join the French Tech 2030 program, Jean-François Déchant, Co-founder and CEO of ELICIT PLANT comments. Our mission is to help the field crop industry everywhere in the world address climate change. The French Tech 2030 project will accelerate our development in France and in the world (Brazil, Ukraine and North America). There is an urgent need to provide innovative solutions to growers, and we are proud to be able to contribute effectively to the necessary agricultural transition with high-performance, reliable products that respect our environment."

About Elicit Plant:

Elicit Plant is an agri-biotech company whose ambition is to become the champion of the ecological transition for agriculture and respond to the global challenges of the impact of climate change on row crops. EliTerra®, Elicit Plant's proprietary technology, is based on the exogenous contribution of phytosterols, a set of molecules of plant origin, which increases the resistance of plants to stress by eliciting their natural defenses. Large-scale field trials - more than 500 trials on 3 continents - have demonstrated that the biosolutions from the Eliterra® Platform are the only ones offering farmers a regular and sufficient return on investment for use on field crops, with an average yield gain of 12%. In 2022, Elicit Plant began marketing its BEST-a product line in France, particularly for corn crops, and has obtained marketing authorizations for Ukraine, Brazil and Europe. For more information: www.elicit-plant.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

anne@lanouvelle-agence.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press Release

Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the deployment of AI Agents. This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. These proven benchmarks serve as the technical foundation for AWAKE’s two interconnected engines, which formalise this efficiency into a repeatable manufacturing process

FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press Release

The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifocal lenses, which rely on multiple optical zones and often require prolonged visual and cognitive adaptation. “We are proud to offer the first contact lens solution for the world’s aging population th

Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press Release

Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources — a cornerstone of the Kingdom’s strategy to diversify its energy portfolio and support the global energy transition. “This agreement is an important step forward in Aramco’s effor

Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press Release

Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals — not

BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press Release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye